Article

Furmonertinib Activity in NSCLC Harboring EGFR L858R and ERBB2 S310F Co-Mutations: A Case Report With Literature Review

2025-07-18

Abstract excerpt

<title>Abstract</title> <p>While targeted therapies have remarkably transformed the landscape of lung adenocarcinoma (LUAD) management, the clinical implications of concurrent mutations in EGFR and ERBB2 remain inadequately understood due to their exceptional rarity in patients. This lack of understanding leads to significant uncertainty regarding therapeutic strategies for individuals with such co-mutations, as...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e3fd31f2-2a15-5774-8507-2f8af5701889
DOI: 10.21203/rs.3.rs-6769788/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Furmonertinib Activity in NSCLC Harboring EGFR L858R and ERBB2 S310F Co-Mutations: A Case Report With Literature ReviewDOI 10.21203/rs.3.rs-6769788/v1Read

Furmonertinib in lung adenocarcinoma with EGFR exon 20 insertion mutation: A case report of positive outcome.Semantic proximity Read

Response to furmonertinib in a patient with non-Small cell lung cancer harboring HER2 exon 21 insertion mutation : a case reportSemantic proximity Read

RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.Semantic proximity Read

Non-small cell lung cancer: an update on emerging EGFR-targeted therapies.Semantic proximity Read

ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer.Semantic proximity Read

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.Semantic proximity Read

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Semantic proximity Read

Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.Semantic proximity Read

The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.Semantic proximity Read

EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort.Semantic proximity Read

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.Semantic proximity Read